Overview Dividends

(ABUS) Arbutus Biopharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: CA03879J1003

RNAi Therapeutic, PD-L1 Inhibitor, Hepatitis B, Clinical Trials

ABUS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 61.13%
EPS Trend (3Y Correlation): 50.8%

ABUS Revenue

Revenue Growth (3Y CAGR): 23.94%
Revenue Trend (3Y Correlation): -42.5%

Risk via 10d forecast
Volatility	42.0%
Value at Risk 5%th	62.9%

Reward
Sharpe Ratio	0.44
Alpha	0.63

Character
Hurst Exponent	0.390
Beta	0.649

Drawdowns 3y
Max DD	45.48%
Mean DD	18.75%

Description: ABUS Arbutus Biopharma October 22, 2025

Arbutus Biopharma Corp (NASDAQ: ABUS) is a U.S.-based clinical-stage biotech that focuses on RNA-interference (RNAi) therapeutics for chronic hepatitis B (HBV). Its lead pipeline includes Imdusiran, a GalNAc-conjugated, subcutaneous RNAi drug currently in Phase 1/2a trials that aims to silence all HBV antigens-including HBsAg-and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b designed to restore HBV-specific immunity by blocking the PD-L1 checkpoint.

Key operational metrics (as of the latest 10-Q) show a cash runway of roughly $65 million, enough to fund R&D through at least 2026 under current burn-rate assumptions, and a net-loss of $48 million for the most recent fiscal year, reflecting heavy trial spend. The HBV market is estimated at $3–4 billion globally, with a projected CAGR of 8-10 % driven by unmet needs for functional cure therapies, which positions Arbutus’s RNAi approach as a potential high-margin niche.

The company’s strategic licensing agreement with Alnylam Pharmaceuticals grants access to lipid-nanoparticle (LNP) delivery technology, a sector-wide driver that has accelerated RNAi commercialization (e.g., Alnylam’s Onpattro and Givlaari). This partnership could reduce development timelines and de-risk scale-up, but the agreement also obligates royalty payments that will dilute future cash flows.

Arbutus rebranded from Tekmira in 2015 and remains headquartered in Warminster, Pennsylvania; its GICS classification is Biotechnology, and it trades as a common stock under the ticker ABUS.

For a deeper, data-driven assessment of ABUS’s valuation dynamics-including peer-adjusted multiples and scenario-based cash-flow modeling-consider exploring the analyst tools on ValueRay.

ABUS Stock Overview

Market Cap in USD	863m
Sub-Industry	Biotechnology
IPO / Inception	2015-08-03
Return 12m vs S&P 500	+6.36%
Analyst Rating	4.25 of 5

ABUS Dividends

Currently no dividends paid

ABUS Growth Ratios

CAGR	20.90%
CAGR/Max DD Calmar Ratio	0.46
CAGR/Mean DD Pain Ratio	1.11
Current Volume	823.6k
Average Volume	823.6k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-54.3m TTM) > 0 and > 6% of Revenue (6% = 925.0k TTM)

FCFTA -0.58 (>2.0%) and ΔFCFTA -13.58pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 636.3% (prev 1249 %; Δ -612.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.58 (>3.0%) and CFO -60.2m <= Net Income -54.3m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 20.53 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (192.4m) change vs 12m ago 2.32% (target <= -2.0% for YES)

Gross Margin 39.65% (prev -63.87%; Δ 103.5pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 11.71% (prev 6.29%; Δ 5.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -470.8 (EBITDA TTM -53.1m / Interest Expense TTM 115.0k) >= 6 (WARN >= 3)

Altman Z'' -39.72

(A) 0.95 = (Total Current Assets 103.1m - Total Current Liabilities 5.02m) / Total Assets 103.3m

(B) -13.25 = Retained Earnings (Balance) -1.37b / Total Assets 103.3m

warn (B) unusual magnitude: -13.25 — check mapping/units

(D) 0.02 = Book Value of Equity 348.0k / Total Liabilities 20.3m

Total Rating: -39.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 31.15

1. Piotroski 1.0pt = -4.0

2. FCF Yield -7.83% = -3.92

3. FCF Margin data missing

4. Debt/Equity 0.06 = 2.50

5. Debt/Ebitda 0.61 = 2.22

6. ROIC - WACC (= -69.07)% = -12.50

7. RoE -59.23% = -2.50

8. Rev. Trend -42.54% = -3.19

9. EPS Trend 50.83% = 2.54

What is the price of ABUS shares?

As of November 11, 2025, the stock is trading at USD 4.50 with a total of 823,589 shares traded.
Over the past week, the price has changed by -1.75%, over one month by +5.39%, over three months by +34.33% and over the past year by +20.64%.

Is Arbutus Biopharma a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Arbutus Biopharma (NASDAQ:ABUS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 31.15 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ABUS is around 4.10 USD . This means that ABUS is currently overvalued and has a potential downside of -8.89%.

Is ABUS a buy, sell or hold?

Arbutus Biopharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy ABUS.

Strong Buy: 2
Buy: 1
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ABUS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	5.2	14.9%
Analysts Target Price	5.2	14.9%
ValueRay Target Price	4.6	2.9%

ABUS Fundamental Data Overview November 10, 2025

Market Cap USD = 862.6m (862.6m USD * 1.0 USD.USD)
P/S = 55.9577
P/B = 10.3732
Beta = 0.649
Revenue TTM = 15.4m USD
EBIT TTM = -54.1m USD
EBITDA TTM = -53.1m USD
Long Term Debt = 1.09m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 514.0k USD (from shortTermDebt, last quarter)
Debt = 5.00m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -32.4m USD (from netDebt column, last quarter)
Enterprise Value = 769.6m USD (862.6m + Debt 5.00m - CCE 98.1m)
Interest Coverage Ratio = -470.8 (Ebit TTM -54.1m / Interest Expense TTM 115.0k)
FCF Yield = -7.83% (FCF TTM -60.3m / Enterprise Value 769.6m)
FCF Margin = -391.0% (FCF TTM -60.3m / Revenue TTM 15.4m)
Net Margin = -351.9% (Net Income TTM -54.3m / Revenue TTM 15.4m)
Gross Margin = 39.65% ((Revenue TTM 15.4m - Cost of Revenue TTM 9.30m) / Revenue TTM)
Gross Margin QoQ = 99.90% (prev -407.9%)
Tobins Q-Ratio = 7.45 (Enterprise Value 769.6m / Total Assets 103.3m)
Interest Expense / Debt = 0.56% (Interest Expense 28.0k / Debt 5.00m)
Taxrate = -0.0% (0.0 / -69.9m)
NOPAT = -54.1m (EBIT -54.1m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 20.53 (Total Current Assets 103.1m / Total Current Liabilities 5.02m)
Debt / Equity = 0.06 (Debt 5.00m / totalStockholderEquity, last quarter 83.0m)
Debt / EBITDA = 0.61 (negative EBITDA) (Net Debt -32.4m / EBITDA -53.1m)
Debt / FCF = 0.54 (negative FCF - burning cash) (Net Debt -32.4m / FCF TTM -60.3m)
Total Stockholder Equity = 91.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -52.54% (Net Income -54.3m / Total Assets 103.3m)
RoE = -59.23% (Net Income TTM -54.3m / Total Stockholder Equity 91.6m)
RoCE = -58.41% (EBIT -54.1m / Capital Employed (Equity 91.6m + L.T.Debt 1.09m))
RoIC = -59.10% (negative operating profit) (NOPAT -54.1m / Invested Capital 91.6m)
WACC = 9.97% (E(862.6m)/V(867.6m) * Re(10.02%) + D(5.00m)/V(867.6m) * Rd(0.56%) * (1-Tc(-0.0)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.88%
Fair Price DCF = unknown (Cash Flow -60.3m)
EPS Correlation: 50.83 | EPS CAGR: 61.13% | SUE: 1.40 | # QB: 2
Revenue Correlation: -42.54 | Revenue CAGR: 23.94% | SUE: 4.0 | # QB: 1

Additional Sources for ABUS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle